Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease
Background Hidradenitis suppurativa (HS) is a debilitating skin condition whose pathogenesis is poorly understood, although interleukin (IL)-23 may play a role. IL-23 is also implicated in the pathogenesis of Crohn’s disease (CD) and psoriasis, both of which can occur in patients with HS. Case repor...
Main Authors: | Hannah S. Berman, Natalie M. Villa, Vivian Y. Shi, Jennifer L. Hsiao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-02-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2019.1654067 |
Similar Items
-
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
by: Martora F, et al.
Published: (2024-02-01) -
Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety
by: Astrid‐Helene Ravn Jørgensen, et al.
Published: (2020-12-01) -
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023-09-01) -
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
by: Federica Repetto, et al.
Published: (2023-04-01) -
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
by: Fabrizio Martora, et al.
Published: (2023-04-01)